Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer

Jinhua Wang, Ashok Sharma, Sharad A. Ghamande, Stephen Bush, Daron Ferris, Wenbo Zhi, Mingfang He, Meiyao Wang, Xiaoxiao Wang, Eric Miller, Diane Hopkins, Michael Macfee, Ruili Guan, Jinhai Tang, Jin Xiong She

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Biomarkers play critical roles in early detection, diagnosis and monitoring of therapeutic outcome and recurrence of cancer. Previous biomarker research on ovarian cancer (OC) has mostly focused on the discovery and validation of diagnostic biomarkers. The primary purpose of this study is to identify serum biomarkers for prognosis and therapeutic outcomes of ovarian cancer. Experimental Design: Forty serum proteins were analyzed in 70 serum samples from healthy controls (HC) and 101 serum samples from serous OC patients at three different disease phases: post diagnosis (PD), remission (RM) and recurrence (RC). The utility of serum proteins as OC biomarkers was evaluated using a variety of statistical methods including survival analysis. Results: Ten serum proteins (PDGF-AB/BB, PDGF-AA, CRP, sFas, CA125, SAA, sTNFRII, sIL-6R, IGFBP6 and MDC) have individually good area-under-the-curve (AUC) values (AUC = 0.69-0.86) and more than 10 three-marker combinations have excellent AUC values (0.91-0.93) in distinguishing active cancer samples (PD & RC) from HC. The mean serum protein levels for RM samples are usually intermediate between HC and OC patients with active cancer (PD & RC). Most importantly, five proteins (sICAM1, RANTES, sgp130, sTNFR-II and sVCAM1) measured at remission can classify, individually and in combination, serous OC patients into two subsets with significantly different overall survival (best HR = 17, p<10 -3). Conclusion: We identified five serum proteins which, when measured at remission, can accurately predict the overall survival of serous OC patients, suggesting that they may be useful for monitoring the therapeutic outcomes for ovarian cancer.

Original languageEnglish (US)
Article numbere78393
JournalPloS one
Volume8
Issue number11
DOIs
StatePublished - Nov 11 2013

Fingerprint

ovarian neoplasms
remission
Ovarian Neoplasms
blood proteins
Blood Proteins
Biomarkers
therapeutics
Survival
biomarkers
Area Under Curve
Recurrence
Cytokine Receptor gp130
Therapeutics
Chemokine CCL5
Monitoring
neoplasms
Tumor Biomarkers
Serum
Design of experiments
Statistical methods

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer. / Wang, Jinhua; Sharma, Ashok; Ghamande, Sharad A.; Bush, Stephen; Ferris, Daron; Zhi, Wenbo; He, Mingfang; Wang, Meiyao; Wang, Xiaoxiao; Miller, Eric; Hopkins, Diane; Macfee, Michael; Guan, Ruili; Tang, Jinhai; She, Jin Xiong.

In: PloS one, Vol. 8, No. 11, e78393, 11.11.2013.

Research output: Contribution to journalArticle

Wang, Jinhua ; Sharma, Ashok ; Ghamande, Sharad A. ; Bush, Stephen ; Ferris, Daron ; Zhi, Wenbo ; He, Mingfang ; Wang, Meiyao ; Wang, Xiaoxiao ; Miller, Eric ; Hopkins, Diane ; Macfee, Michael ; Guan, Ruili ; Tang, Jinhai ; She, Jin Xiong. / Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer. In: PloS one. 2013 ; Vol. 8, No. 11.
@article{7c2d098e384d49a990623ba3d8b52bdb,
title = "Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer",
abstract = "Background: Biomarkers play critical roles in early detection, diagnosis and monitoring of therapeutic outcome and recurrence of cancer. Previous biomarker research on ovarian cancer (OC) has mostly focused on the discovery and validation of diagnostic biomarkers. The primary purpose of this study is to identify serum biomarkers for prognosis and therapeutic outcomes of ovarian cancer. Experimental Design: Forty serum proteins were analyzed in 70 serum samples from healthy controls (HC) and 101 serum samples from serous OC patients at three different disease phases: post diagnosis (PD), remission (RM) and recurrence (RC). The utility of serum proteins as OC biomarkers was evaluated using a variety of statistical methods including survival analysis. Results: Ten serum proteins (PDGF-AB/BB, PDGF-AA, CRP, sFas, CA125, SAA, sTNFRII, sIL-6R, IGFBP6 and MDC) have individually good area-under-the-curve (AUC) values (AUC = 0.69-0.86) and more than 10 three-marker combinations have excellent AUC values (0.91-0.93) in distinguishing active cancer samples (PD & RC) from HC. The mean serum protein levels for RM samples are usually intermediate between HC and OC patients with active cancer (PD & RC). Most importantly, five proteins (sICAM1, RANTES, sgp130, sTNFR-II and sVCAM1) measured at remission can classify, individually and in combination, serous OC patients into two subsets with significantly different overall survival (best HR = 17, p<10 -3). Conclusion: We identified five serum proteins which, when measured at remission, can accurately predict the overall survival of serous OC patients, suggesting that they may be useful for monitoring the therapeutic outcomes for ovarian cancer.",
author = "Jinhua Wang and Ashok Sharma and Ghamande, {Sharad A.} and Stephen Bush and Daron Ferris and Wenbo Zhi and Mingfang He and Meiyao Wang and Xiaoxiao Wang and Eric Miller and Diane Hopkins and Michael Macfee and Ruili Guan and Jinhai Tang and She, {Jin Xiong}",
year = "2013",
month = "11",
day = "11",
doi = "10.1371/journal.pone.0078393",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer

AU - Wang, Jinhua

AU - Sharma, Ashok

AU - Ghamande, Sharad A.

AU - Bush, Stephen

AU - Ferris, Daron

AU - Zhi, Wenbo

AU - He, Mingfang

AU - Wang, Meiyao

AU - Wang, Xiaoxiao

AU - Miller, Eric

AU - Hopkins, Diane

AU - Macfee, Michael

AU - Guan, Ruili

AU - Tang, Jinhai

AU - She, Jin Xiong

PY - 2013/11/11

Y1 - 2013/11/11

N2 - Background: Biomarkers play critical roles in early detection, diagnosis and monitoring of therapeutic outcome and recurrence of cancer. Previous biomarker research on ovarian cancer (OC) has mostly focused on the discovery and validation of diagnostic biomarkers. The primary purpose of this study is to identify serum biomarkers for prognosis and therapeutic outcomes of ovarian cancer. Experimental Design: Forty serum proteins were analyzed in 70 serum samples from healthy controls (HC) and 101 serum samples from serous OC patients at three different disease phases: post diagnosis (PD), remission (RM) and recurrence (RC). The utility of serum proteins as OC biomarkers was evaluated using a variety of statistical methods including survival analysis. Results: Ten serum proteins (PDGF-AB/BB, PDGF-AA, CRP, sFas, CA125, SAA, sTNFRII, sIL-6R, IGFBP6 and MDC) have individually good area-under-the-curve (AUC) values (AUC = 0.69-0.86) and more than 10 three-marker combinations have excellent AUC values (0.91-0.93) in distinguishing active cancer samples (PD & RC) from HC. The mean serum protein levels for RM samples are usually intermediate between HC and OC patients with active cancer (PD & RC). Most importantly, five proteins (sICAM1, RANTES, sgp130, sTNFR-II and sVCAM1) measured at remission can classify, individually and in combination, serous OC patients into two subsets with significantly different overall survival (best HR = 17, p<10 -3). Conclusion: We identified five serum proteins which, when measured at remission, can accurately predict the overall survival of serous OC patients, suggesting that they may be useful for monitoring the therapeutic outcomes for ovarian cancer.

AB - Background: Biomarkers play critical roles in early detection, diagnosis and monitoring of therapeutic outcome and recurrence of cancer. Previous biomarker research on ovarian cancer (OC) has mostly focused on the discovery and validation of diagnostic biomarkers. The primary purpose of this study is to identify serum biomarkers for prognosis and therapeutic outcomes of ovarian cancer. Experimental Design: Forty serum proteins were analyzed in 70 serum samples from healthy controls (HC) and 101 serum samples from serous OC patients at three different disease phases: post diagnosis (PD), remission (RM) and recurrence (RC). The utility of serum proteins as OC biomarkers was evaluated using a variety of statistical methods including survival analysis. Results: Ten serum proteins (PDGF-AB/BB, PDGF-AA, CRP, sFas, CA125, SAA, sTNFRII, sIL-6R, IGFBP6 and MDC) have individually good area-under-the-curve (AUC) values (AUC = 0.69-0.86) and more than 10 three-marker combinations have excellent AUC values (0.91-0.93) in distinguishing active cancer samples (PD & RC) from HC. The mean serum protein levels for RM samples are usually intermediate between HC and OC patients with active cancer (PD & RC). Most importantly, five proteins (sICAM1, RANTES, sgp130, sTNFR-II and sVCAM1) measured at remission can classify, individually and in combination, serous OC patients into two subsets with significantly different overall survival (best HR = 17, p<10 -3). Conclusion: We identified five serum proteins which, when measured at remission, can accurately predict the overall survival of serous OC patients, suggesting that they may be useful for monitoring the therapeutic outcomes for ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84892941529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892941529&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0078393

DO - 10.1371/journal.pone.0078393

M3 - Article

C2 - 24244307

AN - SCOPUS:84892941529

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e78393

ER -